BioSpace News Archive

Jaguar Health, Inc. (NASDAQ:JAGX) announced today that effective December 9, 2020, the Company granted nonstatutory stock options for the purchase of up to 1,500 shares of the Companys common stock to one new employee, and nonstatutory stock options for the purchase of up to 35,000 shares of the Companys common stock

Arena Pharmaceuticals, Inc. announced that on January 15, 2021, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 16,950 shares of its common stock and 3,470 inducement restricted stock units.

The Board of Directors of Sensient Technologies Corporation has declared a regular quarterly cash dividend on its common stock of $0.39 per share.

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Madelyn ‘Lyn’ Caltabiano, Ph.D. to the position of Senior Vice President, Global Program Management. In this newly created role, Dr. Caltabiano will lead and expand the Global Program Management organization for the company’s pipeline and will develop appropriate strategies t

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month

First FDA-approved oral treatment for lupus nephritis represents a significant milestone for people living with lupus-related kidney disease, a leading cause of disability and mortality in lupus

Senseonics Holdings, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 51,948,052 shares of common stock of the Company at a public offering price of $1.925 per share, less underwriting discounts and commissions.

Elekta AB announced that it has sold its 7.3 percent of the outstanding common stock in ViewRay, Inc. Elekta has no remaining shares in ViewRay after the transaction..

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO ™ (berotralstat) 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. ORLADEYO is the first and only prophylactic HAE medication approved in Japan.

The Cooperative Research and Development Agreement (CRADA) with the Department of Defense (DoD) and the Biomedical Advanced Research and Development Authority (BARDA) supports the development of lenzilumab as a potential treatment for patients with COVID-19